KIMS Submits FY26 Integrated Annual Report, Highlights Expansion and Financial Initiatives
KIMS submitted its FY26 Integrated Annual Report. Consolidated revenue grew 28.2% to ₹39,308 million. EBITDA rose 1.6% to ₹8,282 million, while PAT fell 41.7% to ₹2,420 million due to expansion costs. The company raised ₹1,500 crore via QIP, using ₹1,100 crore for debt reduction, and ₹600 crore through promoter preferential allotment.
The submission of the annual report and details on financial performance, including revenue growth and fundraising, are material for stakeholders. The decrease in PAT due to expansion costs is a point of concern that warrants medium impact.
The announcement details significant expansion and revenue growth, which are positive. However, the substantial decrease in PAT and the mention of initial gestation costs temper the overall positive sentiment, leading to a neutral assessment.
Krishna Institute of Medical Sciences Limited (KIMS) has submitted its Integrated Annual Report for the Financial Year 2025-26, as per Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report is available to members electronically and on the company's website.
The report details significant expansion across its network, with the company now operating 27 units across 5 states. This expansion includes recent launches in Mumbai, Bengaluru, Sangli, Kollam, and two units in Guntur, in addition to subsequent launches in Kompally and Palakkad. The company's consolidated revenue for FY26 reached ₹39,308 million, a 28.2% increase from FY25's ₹30,670 million. EBITDA saw a modest growth of 1.6% to ₹8,282 million from ₹8,148 million in FY25. However, Profit After Tax (PAT) decreased by 41.7% to ₹2,420 million from ₹4,148 million in FY25, attributed to initial gestation costs of expansion.
KIMS also undertook significant financial initiatives, including a Qualified Institutional Placement (QIP) that raised ₹1,500 crores, with ₹1,100 crores allocated to debt reduction. Additionally, a preferential allotment to Promoters raised ₹600 crores, with 25% infused initially and the balance to be brought in within 18 months. These initiatives are expected to strengthen the balance sheet and support future growth.
The report also highlights academic achievements, including Dr. Raghuram's third Guinness World Record, the KIMS team winning the ACR Knowledge Bowl 2025, and the achievement of over 10,000 successful brain tumor surgeries. The company emphasized its commitment to clinical excellence, advanced technology adoption, and patient-centric care throughout its expanding network.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under business responsibility and sustainability report (brsr). It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.